A multistep model for ovarian tumorigenesis: The value of mutation analysis in the KRAS and BRAF genes

Journal of Pathology

Volumn 203, Issue 2, 2004, Pages 617-619

  Russell, S E Hilary ^a   McCluggage, W Glenn ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

KRAS and BRAF mutation; Ovarian tumorigenesis

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; CARCINOMA; EVIDENCE BASED MEDICINE; FEMALE; HISTOPATHOLOGY; HUMAN; MUCINOUS CARCINOMA; MUTATIONAL ANALYSIS; OVARY CARCINOMA; PRECANCER; PRIORITY JOURNAL; SEROUS CARCINOMA;

CYSTADENOMA, SEROUS; EPITHELIUM; FEMALE; GENES, RAS; HUMANS; MODELS, BIOLOGICAL; MUTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF;

EID: 2642583203     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1563     Document Type: Article

References (15)

1. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001; 38: 87-95.
2. Bell DA, Scully RE. Early de novo ovarian carcinoma: a study of fourteen cases. Cancer 1994; 73: 1859-1864.
3. Hauptmann S, Dietel M. Serous tumors of low malignant potential of the ovary - molecular pathology: part 2. Virchows Arch 2001; 435: 539-551.
4. Hutson R. Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995; 27: 367-371.
5. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary: a distinctive low grade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996; 20: 1319-1330.
6. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996; 20: 1331- 1345.
7. Smith Sehdev AE, Sehlev PS, Kurman RJ. Non-invasive and invasive micropapillary (low grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol 2003; 27: 725-736.
8. Scully RE, Bell DA, Abu-Jawdeh GM. Update on early ovarian cancer and cancer developing in benign ovarian tumours. In Ovarian Cancer 3, Sharp F, Mason P, Blackett T, Berek J (eds). Chapman & Hall: London, 1995; 139-144.
9. Puls LE, Powell DE, De Priest PD, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992; 47: 53-57.
10. Sieben NLG, Macropoulos P, Roemen GMJM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004; 202: 336-340.
11. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001; 93: 53-62.
12. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 1997; 79: 1581-1586.
13. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95: 484-486.
14. Singer G, Kurman RJ, Chang HW, Cho SK, Shih IeM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002; 160: 1223-1228.
15. Matias-Guiu X, Catasus L, Bussaglia, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 6: 569-577.